{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:57:10Z","timestamp":1793645830719,"version":"4.5.1"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.addr.2020.12.008","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T05:17:51Z","timestamp":1608182271000},"page":"137-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":186,"special_numbering":"C","title":["Non-viral COVID-19 vaccine delivery systems"],"prefix":"10.1016","volume":"169","author":[{"given":"Kyung Soo","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa E.","family":"Aikins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2020.12.008_bb0005","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jmii.2020.03.026","article-title":"The association between international and domestic air traffic and the coronavirus (COVID-19) outbreak","volume":"53","author":"Lau","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.addr.2020.12.008_bb0010","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2020.12.008_bb0015","doi-asserted-by":"crossref","first-page":"104792","DOI":"10.1016\/j.antiviral.2020.104792","article-title":"Coronavirus membrane fusion mechanism offers a potential target for antiviral development","volume":"178","author":"Tang","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2020.12.008_bb0020","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-generation vaccine platforms for COVID-19","volume":"19","author":"van Riel","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2020.12.008_bb0025","author":"BioNTech"},{"key":"10.1016\/j.addr.2020.12.008_bb0030","author":"Moderna"},{"key":"10.1016\/j.addr.2020.12.008_bb0035","first-page":"43","article-title":"Vaccines for COVID-19: The current state of play","volume":"35","author":"Koirala","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.addr.2020.12.008_bb0040","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00151-8","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2020.12.008_bb0045","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV--a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2020.12.008_bb0050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2020.12.008_bb0055","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.12.008_bb0060","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.12.008_bb0065","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase 1\/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.12.008_bb0070","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2020.12.008_bb0075","article-title":"Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine","author":"Sahin","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.addr.2020.12.008_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.addr.2020.12.008_bb0085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2020.12.008_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-62703-260-5_2","article-title":"In vitro transcription of long RNA containing modified nucleosides","volume":"969","author":"Pardi","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2020.12.008_bb0095","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.12.008_bb0100","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.12.008_bb0105","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.12.008_bb0110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2020.12.008_bb0115","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1007\/s12274-018-2091-z","article-title":"Recent advances in mRNA vaccine delivery","volume":"11","author":"Tan","year":"2018","journal-title":"Nano Res."},{"key":"10.1016\/j.addr.2020.12.008_bb0120","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","article-title":"Lipid nanoparticle technology for therapeutic gene regulation in the liver","volume":"159","author":"Witzigmann","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.12.008_bb0125","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2020.12.008_bb0130","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.12.008_bb0135","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2020.12.008_bb0140","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt1402","article-title":"A combinatorial library of lipid-like materials for delivery of RNAi therapeutics","volume":"26","author":"Akinc","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.12.008_bb0145","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1073\/pnas.1322937111","article-title":"Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates","volume":"111","author":"Dong","year":"2014","journal-title":"Proceed. Nation. Acad. Sci. U.S.A."},{"key":"10.1016\/j.addr.2020.12.008_bb0150","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.12.008_bb0155","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1021\/acs.nanolett.5b03528","article-title":"An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo","volume":"15","author":"Li","year":"2015","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2020.12.008_bb0160","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jconrel.2014.12.029","article-title":"A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma","volume":"200","author":"Akita","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.12.008_bb0165","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2019.03.003","article-title":"Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets","volume":"27","author":"Conway","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.12.008_bb0170","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.12.008_bb0175","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nbt.1733","article-title":"Expression of therapeutic proteins after delivery of chemically modified mRNA in mice","volume":"29","author":"Kormann","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.12.008_bb0180","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nbt.2682","article-title":"Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction","volume":"31","author":"Zangi","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.12.008_bb0185","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00262-005-0064-z","article-title":"Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor\/self antigen","volume":"55","author":"Hess","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.addr.2020.12.008_bb0190","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.12.008_bb0195","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.2217\/nnm-2016-0275","article-title":"Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma","volume":"11","author":"Grabbe","year":"2016","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.addr.2020.12.008_bb0200","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.nano.2015.11.001","article-title":"Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines","volume":"12","author":"Demoulins","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2020.12.008_bb0205","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12195-018-0536-9","article-title":"Lipid polymer hybrid nanomaterials for mRNA delivery","volume":"11","author":"Zhao","year":"2018","journal-title":"Cell. Mol. Bioeng."},{"key":"10.1016\/j.addr.2020.12.008_bb0210","first-page":"E448","article-title":"Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals","volume":"114","author":"McKinlay","year":"2017","journal-title":"Proceed. Nation. Acad. Sci. U.S.A."},{"key":"10.1016\/j.addr.2020.12.008_bb0215","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1021\/acs.nanolett.5b02428","article-title":"Poly(glycoamidoamine) brushes formulated nanomaterials for systemic siRNA and mRNA delivery in vivo","volume":"16","author":"Dong","year":"2016","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2020.12.008_bb0220","doi-asserted-by":"crossref","first-page":"13808","DOI":"10.1002\/anie.201608450","article-title":"Polymer-lipid nanoparticles for systemic delivery of mRNA to the lungs","volume":"55","author":"Kaczmarek","year":"2016","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2020.12.008_bb0225","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biomaterials.2017.02.019","article-title":"Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination","volume":"125","author":"Persano","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2020.12.008_bb0230","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.biomaterials.2015.12.031","article-title":"Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety","volume":"82","author":"Uchida","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2020.12.008_bb0235","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.3109\/10717544.2015.1038856","article-title":"Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA","volume":"23","author":"Zhao","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2020.12.008_bb0240","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/mt.2014.133","article-title":"A cationic nanoemulsion for the delivery of next-generation RNA vaccines","volume":"22","author":"Brito","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.12.008_bb0245","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular mechanisms for enhanced DNA vaccine immunogenicity","volume":"15","author":"Li","year":"2016","journal-title":"Expert. Rev. Vaccines"},{"key":"10.1016\/j.addr.2020.12.008_bb0250","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2020.12.008_bb0255","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1586\/erv.09.84","article-title":"DNA vaccine manufacture: scale and quality","volume":"8","author":"Cai","year":"2009","journal-title":"Expert. Rev. Vaccines"},{"key":"10.1016\/j.addr.2020.12.008_bb0260","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1021\/js970367a","article-title":"Analysis of plasmid DNA from a pharmaceutical perspective","volume":"87","author":"Middaugh","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2020.12.008_bb0265","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.molimm.2017.02.011","article-title":"Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD","volume":"85","author":"Garg","year":"2017","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.addr.2020.12.008_bb0270","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.12.008_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113605","article-title":"DNA vaccines-how far from clinical use?","volume":"19","author":"Hobernik","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2020.12.008_bb0280","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.addr.2020.12.008_bb0285","doi-asserted-by":"crossref","first-page":"11478","DOI":"10.1073\/pnas.90.24.11478","article-title":"DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations","volume":"90","author":"Fynan","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.12.008_bb0290","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1086\/515613","article-title":"First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response","volume":"178","author":"MacGregor","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2020.12.008_bb0295","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2020.12.008_bb0300","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","article-title":"A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial","volume":"26","author":"Martin","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2020.12.008_bb0305","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2020.12.008_bb0310","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2020.12.008_bb0315","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.4161\/hv.24702","article-title":"Tolerability of intramuscular and intradermal delivery by CELLECTRA((R)) adaptive constant current electroporation device in healthy volunteers","volume":"9","author":"Diehl","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.addr.2020.12.008_bb0320","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2020.12.008_bb0325","author":"Inovio"},{"key":"10.1016\/j.addr.2020.12.008_bb0330","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/jmv.23768","article-title":"Oral vaccination with a liposome-encapsulated influenza DNA vaccine protects mice against respiratory challenge infection","volume":"86","author":"Liu","year":"2014","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.addr.2020.12.008_bb0335","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1586\/erv.09.61","article-title":"Mucosal vaccines: novel advances in technology and delivery","volume":"8","author":"Yuki","year":"2009","journal-title":"Expert. Rev. Vaccines"},{"key":"10.1016\/j.addr.2020.12.008_bb0340","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0003-9861(92)90684-O","article-title":"Fragmentation of dimyristoylphosphatidylcholine vesicles by apomyoglobin","volume":"297","author":"Lee","year":"1992","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.addr.2020.12.008_bb0345","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.3389\/fimmu.2020.01880","article-title":"The 2020 pandemic: current SARS-CoV-2 vaccine development","volume":"11","author":"Alturki","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2020.12.008_bb0350","author":"Symvivo"},{"key":"10.1016\/j.addr.2020.12.008_bb0355","author":"Ho"},{"key":"10.1016\/j.addr.2020.12.008_bb0360","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0140-6736(14)60524-9","article-title":"Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial","volume":"384","author":"McAllister","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.12.008_bb0365","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1016\/j.vaccine.2015.07.013","article-title":"Effect of jet injection on infectivity of measles, mumps, and rubella vaccine in a bench model","volume":"33","author":"Coughlin","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2020.12.008_bb0370","article-title":"A DNA prime immuno-potentiates a modified live vaccine against the porcine reproductive and respiratory syndrome virus but does not improve heterologous protection","volume":"11","author":"Bernelin-Cottet","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2020.12.008_bb0375","author":"Akst"},{"key":"10.1016\/j.addr.2020.12.008_bb0380","author":"News"},{"key":"10.1016\/j.addr.2020.12.008_bb0385","author":"Firstpost"},{"key":"10.1016\/j.addr.2020.12.008_bb0390","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.3892\/or.2017.5633","article-title":"CpG oligodeoxynucleotides augment antitumor efficacy of folate receptor \u03b1 based DNA vaccine","volume":"37","author":"Qiu","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.addr.2020.12.008_bb0395","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/107999000312450","article-title":"Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo","volume":"20","author":"Kim","year":"2000","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.addr.2020.12.008_bb0400","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/sji.12633","article-title":"MUC1- and survivin-based DNA vaccine combining immunoadjuvants CpG and interleukin-2 in a bicistronic expression plasmid generates specific immune responses and antitumour effects in a murine colorectal carcinoma model","volume":"87","author":"Liu","year":"2018","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.addr.2020.12.008_bb0405","first-page":"168","article-title":"Antitumor effect of a DNA vaccine harboring prostate cancer-specific antigen with IL-12 as an intramolecular adjuvant","volume":"27","author":"Yang","year":"2017","journal-title":"J. Mol. Microbiol. Biotechnol."},{"key":"10.1016\/j.addr.2020.12.008_bb0410","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jconrel.2017.11.025","article-title":"Microneedle arrays coated with charge reversal pH-sensitive copolymers improve antigen presenting cells-homing DNA vaccine delivery and immune responses","volume":"269","author":"Duong","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.12.008_bb0415","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biomaterials.2018.09.008","article-title":"Smart vaccine delivery based on microneedle arrays decorated with ultra-pH-responsive copolymers for cancer immunotherapy","volume":"185","author":"Duong","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2020.12.008_bb0420","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41565-020-0737-y","article-title":"COVID-19 vaccine development and a potential nanomaterial path forward","volume":"15","author":"Shin","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2020.12.008_bb0425","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Thanh Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2020.12.008_bb0430","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice","author":"Tian","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.addr.2020.12.008_bb0435","first-page":"1089","article-title":"Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate","volume":"370","author":"Bangaru","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.addr.2020.12.008_bb0440","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.vaccine.2013.01.039","article-title":"Immune enhancing properties of the novel Matrix-M\u2122 adjuvant leads to potentiated immune responses to an influenza vaccine in mice","volume":"31","author":"Magnusson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2020.12.008_bb0445","article-title":"First-in-human trial of a SARS CoV 2 recombinant spike protein nanoparticle vaccine","author":"Keech","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.addr.2020.12.008_bb0450","doi-asserted-by":"crossref","first-page":"102743","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development","volume":"55","author":"Kim","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2020.12.008_bb0455","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nmat2960","article-title":"Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses","volume":"10","author":"Moon","year":"2011","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2020.12.008_bb0460","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.4049\/jimmunol.1202654","article-title":"Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection","volume":"190","author":"Knuschke","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2020.12.008_bb0465","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1535-7163.MCT-18-0764","article-title":"A tumor-peptide-based nanoparticle vaccine elicits efficient tumor growth control in antitumor immunotherapy","volume":"18","author":"He\u00dfe","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2020.12.008_bb0470","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.addr.2020.12.008_bb0475","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12979-019-0167-6","article-title":"Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge","volume":"16","author":"Hodgins","year":"2019","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.addr.2020.12.008_bb0480","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.vaccine.2018.02.106","article-title":"Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy","volume":"36","author":"Lindsay","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2020.12.008_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216533","article-title":"Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and \u226550 years old adults","volume":"14","author":"Pillet","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2020.12.008_bb0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2007.11.009","article-title":"Determination and application of immunodominant regions of SARS coronavirus spike and nucleocapsid proteins recognized by sera from different animal species","volume":"331","author":"Yu","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.addr.2020.12.008_bb0495","article-title":"Mapping the immunodominance landscape of SARS-CoV-2 spike protein for the design of vaccines against COVID-19","author":"Huang","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2020.12.008_bb0500","doi-asserted-by":"crossref","first-page":"104236","DOI":"10.1016\/j.micpath.2020.104236","article-title":"Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2","volume":"145","author":"Kalita","year":"2020","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.addr.2020.12.008_bb0505","doi-asserted-by":"crossref","first-page":"10895","DOI":"10.1038\/s41598-020-67749-1","article-title":"A candidate multi-epitope vaccine against SARS-CoV-2","volume":"10","author":"Kar","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2020.12.008_bb0510","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2683286","article-title":"Design of a multiepitope-based peptide vaccine against the E protein of human COVID-19: an immunoinformatics approach","volume":"2020","author":"Abdelmageed","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2020.12.008_bb0515","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an Adjuvant System containing \u03b1-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Gar\u00e7on","year":"2012","journal-title":"Expert. Rev. Vaccines"},{"key":"10.1016\/j.addr.2020.12.008_bb0520","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59(\u00ae) adjuvant: a phoenix that arose from the ashes","volume":"12","author":"O'Hagan","year":"2013","journal-title":"Expert. Rev. Vaccines"},{"key":"10.1016\/j.addr.2020.12.008_bb0525","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-4939-6445-1_2","article-title":"Development of the CpG adjuvant 1018: a case study","volume":"1494","author":"Campbell","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2020.12.008_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7774\/cevr.2015.4.1.1","article-title":"Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases","volume":"4","author":"Grunwald","year":"2015","journal-title":"Clin. Exp. Vaccine Res."},{"key":"10.1016\/j.addr.2020.12.008_bb0535","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.0022-202X.2004.23208.x","article-title":"CpG motifs are efficient adjuvants for DNA cancer vaccines","volume":"123","author":"Schneeberger","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.addr.2020.12.008_bb0540","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1016\/S0264-410X(01)00090-1","article-title":"Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization","volume":"19","author":"Reyes","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2020.12.008_bb0545","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1016\/j.vaccine.2009.08.075","article-title":"Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA","volume":"27","author":"Vilalta","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2020.12.008_bb0550","first-page":"5","article-title":"3M-052, a synthetic TLR-7\/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates","author":"Kasturi","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.addr.2020.12.008_bb0555","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4049\/immunohorizons.1700063","article-title":"Recent advances in the discovery and delivery of TLR7\/8 agonists as vaccine adjuvants","volume":"2","author":"Dowling","year":"2018","journal-title":"Immunohorizons"},{"key":"10.1016\/j.addr.2020.12.008_bb0560","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.12.008_bb0565","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.12.008_bb0570","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF03402065","article-title":"Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates","volume":"5","author":"McCluskie","year":"1999","journal-title":"Mol. Med."},{"key":"10.1016\/j.addr.2020.12.008_bb0575","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0161-5890(03)00024-5","article-title":"DNA immunization via intramuscular and intradermal routes using a gene gun provides different magnitudes and durations on immune response","volume":"39","author":"Ito","year":"2003","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.addr.2020.12.008_bb0580","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.3389\/fimmu.2018.02224","article-title":"Nanoparticle vaccines against infectious diseases","volume":"9","author":"Pati","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2020.12.008_bb0585","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1039\/C8BM01272E","article-title":"In vivo targeting of DNA vaccines to dendritic cells using functionalized gold nanoparticles","volume":"7","author":"Gulla","year":"2019","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.addr.2020.12.008_bb0590","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.addr.2020.12.008_bb0595","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0923-2516(97)89892-5","article-title":"\"Naked\" DNA transfer technology for genetic vaccination against infectious disease","volume":"148","author":"Fazio","year":"1997","journal-title":"Res. Virol."},{"key":"10.1016\/j.addr.2020.12.008_bb0600","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.vaccine.2009.12.058","article-title":"Quantitative analysis of influenza virus-specific B cell memory generated by different routes of inactivated virus vaccination","volume":"28","author":"Joo","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2020.12.008_bb0605","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1016\/j.vaccine.2009.03.040","article-title":"Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1\/Th2 bias in the immune response and protection against infection","volume":"27","author":"Mann","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2020.12.008_bb0610","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1016\/S0264-410X(00)00537-5","article-title":"Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes)","volume":"19","author":"Conacher","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2020.12.008_bb0615","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2144\/000112593","article-title":"Long-term storage of DNA-free RNA for use in vaccine studies","volume":"43","author":"Jones","year":"2007","journal-title":"Biotechniques"},{"key":"10.1016\/j.addr.2020.12.008_bb0620","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2020.12.008_bb0625","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/infdis\/jiz132","article-title":"Intradermal SynCon\u00ae Ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers","volume":"220","author":"Tebas","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2020.12.008_bb0630","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.addr.2020.12.008_bb0635","doi-asserted-by":"crossref","first-page":"11409","DOI":"10.1038\/s41598-019-47657-9","article-title":"Ensilication improves the thermal stability of the tuberculosis antigen Ag85b and an Sbi-Ag85b vaccine conjugate","volume":"9","author":"Wahid","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2020.12.008_bb0640","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau4819","article-title":"Novel technology for storage and distribution of live vaccines and other biological medicines at ambient temperature","volume":"6","author":"Bajrovic","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2020.12.008_bb0645","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1158\/1078-0432.CCR-10-3272","article-title":"Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial","volume":"17","author":"Ribas","year":"2011","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.addr.2020.12.008_bb0650","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1073\/pnas.051630798","article-title":"Intralymphatic immunization enhances DNA vaccination","volume":"98","author":"Maloy","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.12.008_bb0655","first-page":"837","article-title":"Critical size limit of biodegradable nanoparticles for enhanced lymph node trafficking and paracortex penetration","volume":"12","author":"Howard","year":"2019","journal-title":"Res. Article"},{"key":"10.1016\/j.addr.2020.12.008_bb0660","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2011.04.081","article-title":"Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines","volume":"29","author":"Carstens","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2020.12.008_bb0665","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature12978","article-title":"Structure-based programming of lymph-node targeting in molecular vaccines","volume":"507","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.12.008_bb0670","article-title":"A lymph node targeted amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2","author":"Steinbuck","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2020.12.008_bb0675","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1021\/mp500589c","article-title":"Rapid and persistent delivery of antigen by lymph node targeting PRINT nanoparticle vaccine carrier to promote humoral immunity","volume":"12","author":"Mueller","year":"2015","journal-title":"Mol. Pharm."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X20302799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X20302799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:57:05Z","timestamp":1759208225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X20302799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":135,"alternative-id":["S0169409X20302799"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2020.12.008","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-viral COVID-19 vaccine delivery systems","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2020.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}